Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient. - Meijer TG; Martens JWM; Prager-van der Smissen WJC; Verkaik NS; Beaufort CM; van Herk S; Robert-Finestra T; Hoogenboezem RM; Ruigrok-Ritstier K; Paul MW; Gribnau J; Bindels EMJ; et al. (Cancers, 2024)